ranolazine has been researched along with methyl 5-(n-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)morpholine-4-carboxamido)pentanoate in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arrhenius, T; Barr, R; Brown, S; Chen, M; Cheng, JF; Dyck, JR; Haramura, M; Harmon, C; Liu, B; Lopaschuk, GD; Mak, CC; Nadzan, AM; Reily, S; Thorn, V; Tith, S; Wallace, D | 1 |
1 other study(ies) available for ranolazine and methyl 5-(n-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)morpholine-4-carboxamido)pentanoate
| Article | Year |
|---|---|
Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors.
Topics: Animals; Carboxy-Lyases; Energy Metabolism; Fatty Acids; Glucose; In Vitro Techniques; Male; Malonyl Coenzyme A; Morpholines; Myocardial Ischemia; Myocardium; Oxidation-Reduction; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Swine | 2006 |